巴西替尼治疗2019年重症冠状病毒病疗效观察

IF 0.2 Q4 RESPIRATORY SYSTEM
Ahmed Amer, Doaa Mousa, Azza Ahmed
{"title":"巴西替尼治疗2019年重症冠状病毒病疗效观察","authors":"Ahmed Amer, Doaa Mousa, Azza Ahmed","doi":"10.4103/ecdt.ecdt_83_22","DOIUrl":null,"url":null,"abstract":"Background Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with the intracellular signaling pathway of many cytokines and in combination with remdesivir may give good results in severe COVID-19 infection. Aim The aim was to assess the effect of baricitinib in severe COVID-19 pneumonia. Patients and methods A total of 30 patients with SARS-CoV-2-confirmed positive cases by nasopharyngeal swab/reverse transcriptase PCR with severe pneumonia received oral baricitinib 4 mg daily, and patients were followed for at least 14 days, unless previously discharged or dead. Results Patients were admitted to the ICU, with a mean duration of 11 days. All patients received high-flow oxygen with nonrebreathing mask. A total of 18 (60%) patients improved and 12 (40%) patients died. Moreover, 15 patients had comorbidities, and mortality was high in this group (10 patients). No serious adverse effects of baricitinib were detected in our study. All patients were hypoxic at admission. The mean oxygen saturation on room air was 70%. There was a statistically significant improvement in oxygenation on discharge after receiving treatment, with mean oxygen saturation of 90% on room air. Conclusion Baricitinib with remdesivir improves clinical status and oxygen saturation in patients with severe COVID-19 pneumonia with no serious adverse effects.","PeriodicalId":46359,"journal":{"name":"Egyptian Journal of Chest Diseases and Tuberculosis","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of baricitinib in severe coronavirus disease 2019\",\"authors\":\"Ahmed Amer, Doaa Mousa, Azza Ahmed\",\"doi\":\"10.4103/ecdt.ecdt_83_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with the intracellular signaling pathway of many cytokines and in combination with remdesivir may give good results in severe COVID-19 infection. Aim The aim was to assess the effect of baricitinib in severe COVID-19 pneumonia. Patients and methods A total of 30 patients with SARS-CoV-2-confirmed positive cases by nasopharyngeal swab/reverse transcriptase PCR with severe pneumonia received oral baricitinib 4 mg daily, and patients were followed for at least 14 days, unless previously discharged or dead. Results Patients were admitted to the ICU, with a mean duration of 11 days. All patients received high-flow oxygen with nonrebreathing mask. A total of 18 (60%) patients improved and 12 (40%) patients died. Moreover, 15 patients had comorbidities, and mortality was high in this group (10 patients). No serious adverse effects of baricitinib were detected in our study. All patients were hypoxic at admission. The mean oxygen saturation on room air was 70%. There was a statistically significant improvement in oxygenation on discharge after receiving treatment, with mean oxygen saturation of 90% on room air. Conclusion Baricitinib with remdesivir improves clinical status and oxygen saturation in patients with severe COVID-19 pneumonia with no serious adverse effects.\",\"PeriodicalId\":46359,\"journal\":{\"name\":\"Egyptian Journal of Chest Diseases and Tuberculosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Egyptian Journal of Chest Diseases and Tuberculosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ecdt.ecdt_83_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Journal of Chest Diseases and Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ecdt.ecdt_83_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒病(COVID-19)通过病毒刺突蛋白与血管紧张素转换酶结合,引发炎症级联反应。Baricitinib是一种口服药物,是Janus激酶(JAK) 1和2的选择性抑制剂,干扰多种细胞因子的细胞内信号通路,与remdesivir合用可能对COVID-19重症感染有很好的效果。目的评价巴西替尼治疗重症COVID-19肺炎的疗效。患者和方法对30例经鼻咽拭子/逆转录酶PCR确诊的sars - cov -2阳性重症肺炎患者口服巴西替尼4 mg /天,随访至少14天,除非患者此前出院或死亡。结果患者均入住ICU,平均住院时间11 d。所有患者均使用无呼吸面罩给予高流量吸氧。共有18例(60%)患者得到改善,12例(40%)患者死亡。此外,15例患者有合并症,本组死亡率高(10例)。本研究未发现巴西替尼的严重不良反应。所有患者入院时均为缺氧。室内空气平均氧饱和度为70%。治疗后出院时氧合改善有统计学意义,室内空气平均氧饱和度为90%。结论巴西替尼联合瑞德西韦可改善COVID-19重症肺炎患者的临床状态和血氧饱和度,无严重不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of baricitinib in severe coronavirus disease 2019
Background Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with the intracellular signaling pathway of many cytokines and in combination with remdesivir may give good results in severe COVID-19 infection. Aim The aim was to assess the effect of baricitinib in severe COVID-19 pneumonia. Patients and methods A total of 30 patients with SARS-CoV-2-confirmed positive cases by nasopharyngeal swab/reverse transcriptase PCR with severe pneumonia received oral baricitinib 4 mg daily, and patients were followed for at least 14 days, unless previously discharged or dead. Results Patients were admitted to the ICU, with a mean duration of 11 days. All patients received high-flow oxygen with nonrebreathing mask. A total of 18 (60%) patients improved and 12 (40%) patients died. Moreover, 15 patients had comorbidities, and mortality was high in this group (10 patients). No serious adverse effects of baricitinib were detected in our study. All patients were hypoxic at admission. The mean oxygen saturation on room air was 70%. There was a statistically significant improvement in oxygenation on discharge after receiving treatment, with mean oxygen saturation of 90% on room air. Conclusion Baricitinib with remdesivir improves clinical status and oxygen saturation in patients with severe COVID-19 pneumonia with no serious adverse effects.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
46
审稿时长
22 weeks
期刊介绍: The journal will cover technical and clinical studies related to health, ethical and social issues in field of The Egyptian Journal of Chest Diseases and Tuberculosis aims to publish and inform readers and all chest physicians of the progress in medical research concerning all aspect of chest diseases. Publications include original articles review articles, editorials, case studies and reports which are relevant to chest diseases. The Journal also aims to highlight recent updates in chest medicine. . Articles with clinical interest and implications will be given preference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信